نتایج جستجو برای: سلولهای t مهندسی شده car t cell

تعداد نتایج: 2678626  

2015
Dina Schneider Ying Xiong Andre Roy Andrew Kaiser Boro Dropulic Rimas Orentas

Adoptive immunotherapy with chimeric antigen receptor (CAR) transduced T lymphocytes has shown promising results in both pediatric and adult B cell malignancies. Nevertheless, both CAR-based and antibody-based antiCD19 therapies, e.g. blinatumomab, have seen treatment failures attributed to the loss of CD19 or an epitope of CD19 on the surface of the malignant B cell. It may be possible to over...

Journal: :memo - Magazine of European Medical Oncology 2020

Journal: :E3S web of conferences 2021

Relapse or refractory B-cell malignancies have been reported in multiple clinical trials after treatment of Anti-CD19 Chimeric Antigen Receptor (CAR) T-cells. Many studies demonstrated the potential immune escape mechanism for like genetic mutation, transcriptional deregulation, lineage switch, loss CAR T-cells, and trogocytosis. The study these mechanisms can provide us insights designs future...

2017
Adam Ajina John Maher

With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipa...

Journal: :Blood 2012
James N Kochenderfer Mark E Dudley Steven A Feldman Wyndham H Wilson David E Spaner Irina Maric Maryalice Stetler-Stevenson Giao Q Phan Marybeth S Hughes Richard M Sherry James C Yang Udai S Kammula Laura Devillier Robert Carpenter Debbie-Ann N Nathan Richard A Morgan Carolyn Laurencot Steven A Rosenberg

We conducted a clinical trial to assess adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR). Our clinical protocol consisted of chemotherapy followed by an infusion of anti-CD19-CAR-transduced T cells and a course of IL-2. Six of the 8 patients treated on our protocol obtained remissions of their advanced, progressive B-cell malignancies. Four of...

2013
Markus Chmielewski Andreas A. Hombach Hinrich Abken

Adoptive T-cell therapy has recently shown promise in initiating a lasting anti-tumor response with spectacular therapeutic success in some cases. Specific T-cell therapy, however, is limited since a number of cancer cells are not recognized by T cells due to various mechanisms including the limited availability of tumor-specific T cells and deficiencies in antigen processing or major histocomp...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید